From bench chemistry to research management, I have twenty-eight years of experience in the pharmaceutical industry.
As the first medicinal chemist at ICOS I had the rare opportunity to build a small but top notch medicinal chemistry group. Along with our biology collegues, we placed eight small molecules into development. Three of these remain in clinical trials: IC-776, IC-83/LY2603618, and CAL-101. Each of these drugs originated in-house as high-throughput screening hits.
Our group worked with a wide network of collaborators and contractors who contributed to our SAR programs: Abbott, Albany Molecular, Array Biopharma, Biogen-Idec, CombiChem, Coromed, Gateway Chemical (now IQSynthesis) Glaxo-Wellcome.
In 2007 I co-founded Afya World Medicines, a non-profit pharmaceutical compa